Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.

Boris RevolloLaura ViñuelaLorena de la MoraFederico Garcia Marc Noguera-JulianMariona PareraRoger ParedesJosep Maria Llibre

Published in: The Journal of antimicrobial chemotherapy (2022)

This case illustrates that integrase resistance can emerge in patients treated with co-formulated dolutegravir/lamivudine and raises awareness of the need to carefully consider and monitor drug-drug interactions, even when regarded as having a low potential, in subjects treated with dolutegravir/lamivudine.

Keyphrases

hiv infected patients
antiretroviral therapy
hiv infected
hiv positive
human immunodeficiency virus
hiv aids
emergency department
risk assessment
newly diagnosed
adverse drug
hiv testing
climate change
human health